Aslan Pharmaceuticals Ltd ADR (ASLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2021 | 06-2021 | 03-2021 | 12-2020 | 09-2020 | |
| Operating Expenses | 8,030 | 14,689 | 6,856 | 5,915 | 3,533 |
| Operating Income | -8,030 | -14,689 | -6,856 | -5,915 | -3,533 |
| Interest Expense | 498 | 615 | 412 | 326 | 244 |
| Other Income | -26 | 2,886 | 297 | 567 | -199 |
| Pre-tax Income | -8,555 | -12,419 | -6,970 | -5,675 | -3,975 |
| Income Tax | N/A | N/A | N/A | N/A | -231 |
| Net Income Continuous | -8,555 | -12,419 | -6,970 | -5,905 | -3,744 |
| Minority Interests | N/A | -269 | N/A | -377 | -268 |
| Net Income | $-8,555 | $-12,150 | $-6,970 | $-5,529 | $-3,476 |
| EPS Basic Total Ops | -4.80 | -8.00 | -5.20 | -4.80 | -4.00 |
| EPS Basic Continuous Ops | -4.91 | -8.20 | -5.42 | -6.01 | -3.94 |
| EPS Diluted Total Ops | -4.80 | -8.00 | -5.20 | -4.80 | -4.00 |
| EPS Diluted Continuous Ops | -4.91 | -8.20 | -5.42 | -6.01 | -3.94 |
| EBITDA(a) | $N/A | $-14,689 | $-6,856 | $-5,842 | $-3,459 |